- Details
- Description
-
Packaging Size21T/Bottle
-
Strength30mg&90mg
-
CompositonBrigatinib
-
TreatmentALK+ non-small cell lung cancer (NSCLC)
-
FormTablet
-
BrandBeigani
-
Quantity Unit30mg&90mg*21T/bottle
-
ManufacturerTongmeng (Lao) Pharmaceutical & Food Co., Ltd.(TLPH)
Brigatinib is a targeted cancer drug treatment for non small cell lung cancer (NSCLC). It is also known as Alunbrig. It is a treatment for a type of lung cancer called non small cell lung cancer (NSCLC) that has spread to other parts of the body (advanced or metastatic NSCLC).
Non-Small Cell Lung Cancer
Indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
90 mg PO qDay for the first 7 days; if 90 mg/day tolerated, increase to 180 mg PO qDay
Continue until disease progression or unacceptable toxicity
Dosage Modifications
If treatment is interrupted for ≥14 days for reasons other than adverse reactions, resume at 90 mg qDay for 7 days before increasing to previously tolerated dose
Dose reductions
Once discontinued, do not subsequently increase dose
Permanently discontinue if unable to tolerate 60 mg/day
-
90 mg/day dose
- First reduction: 60 mg qDay
-
180 mg/day dose
- First reduction: 120 mg qDay
- Second reduction: 90 mg qDay
- Third reduction: 60 mg qDay